bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.

bluebird bio, Inc.

bluebird bio is a biotechnology company that develops gene therapies for severe genetic diseases and cancer.

bluebird bio

bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days.

With a dedicated focus on severe genetic diseases, bluebird has industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward.

Founded in 2010, bluebird has the largest and deepest ex-vivo gene therapy data set in the world—setting the standard for the industry. Today, bluebird continues to forge new paths, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds.

Community guidelines: http://bit.ly/bbbGuidelines

TC BioPharm

Hercules Capital

ARCH Venture Partners

Easton Capital

Third Rock Ventures

TVM Capital

RA Capital Management

ArmaVir Partners

Deerfield Partners

Forbion Capital Partners

California Institute for Regenerative Medicine

Meet Azizi Coleman, Patient and Community Liaison, and member of the bPACE flock. She shares some unique fun facts about herself as well as what inspires her every day as part of the team at bluebird bio.

The flock was thrilled to welcome sickle cell warrior, advocate, and member of the LGBTQ+ community, Andrè Marcel Harris, to the nest for a conversation about the many aspects of Andrè's experience – his race, sexual identity, faith, and more – that intersect and overlap to shape his journey with sickle cell disease. 

Along with sharing his lived experiences, he also visited our lab to meet with some of the minds behind our science and participated in the flock’s Juneteenth celebrations. Warriors like Andrè inspire us to fly higher every day – thank you for joining us at the nest, Andrè!

Holy COW, the flock had a great time at the Cooley's Anemia Foundation Patient-Family Conference! 

It's always an honor connecting with the #betathalassemia community and learning more about how we can better serve people living with beta-thalassemia. And it’s especially fun when our Director of Patient Advocacy, Susan Brisendine, gets the chance to rock her inflatable cow costume at the conference’s costume party! 🐮

The flock had an amazing time at Foundation for Sickle Cell Disease Research’s 18th Annual Sickle Cell Disease Research & Educational Symposium. Our birds were grateful for the opportunity to attend and hear from leaders and members of the #sicklecell community.
 
As Shanna Gillis, Manager of Patient Advocacy, shared: “My first experience at FSCDR was phenomenal! The level of authentic engagement with the community and the thought-provoking educational opportunities were unmatched. I’m looking forward to bringing all my learnings back to the nest so the flock can continue to grow and improve.”

Welcome to our bPACE birds’ series! 

Did you know we have a specific flock of birds, bPACE, who work to educate the communities we serve about gene therapy? 

Meet Phill Okwo, Director of Patient and Community Education, one of our birds who soars to great heights. 

Learn more about Phill and what inspires him.

Last week, members of the flock migrated to #BIO2024. Here are some of the highlights of our team flying high:
➟ We shared perspective (and some hard-won lessons!) from a decade of gene therapy leadership during a fireside chat with Andrew Dunn from Endpoints News.
➟ We facilitated a conversation among pioneers from across the healthcare ecosystem who are blazing the trail for gene therapy access in the commercial setting.
➟ We took a training hike for Luke Timmerman's Timmerman Traverse with others from across the industry who are committed to paying it forward.
➟ We heard BIO International Convention’s new CEO John F. Crowley talk about his vision for the industry and the importance of keeping patients at the heart of our work, specifically sharing the New York Times piece highlighting sickle cell disease gene therapy.
➟ We connected with advocates and other innovators who are committed to changing the world for patients and families.
➟ We celebrated how far we’ve come and all that is ahead – for bluebird, for the field of gene therapy, and for patients and their families.

	Dec '13	Dec '14	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue	20.18M -	25.42M 25.97%	14.08M 44.62%	6.16M 56.28%	35.43M 475.58%	54.58M 54.06%	44.67M 18.15%	250.73M 461.25%	3.66M 98.54%	3.60M 1.77%	29.50M 720.04%
cost of revenue					1.53M -	885K 42.04%	2.98M 236.50%	5.40M 81.20%	38.86M 620.11%	10.08M 74.07%	33.53M 232.71%
gross profit	20.18M -	25.42M 25.97%	14.08M 44.62%	6.16M 56.28%	33.90M 450.77%	53.69M 58.39%	41.70M 22.35%	245.34M 488.40%	-35.20M 114.35%	-6.48M 81.59%	-4.03M 37.81%
selling and marketing expenses
general and administrative expenses	14.13M -	23.23M 64.43%	46.21M 98.95%	65.12M 40.92%	93.55M 43.66%	174.13M 86.13%
selling general and administrative expenses	14.13M -	23.23M 64.43%	46.21M 98.95%	65.12M 40.92%	93.55M 43.66%	174.13M 86.13%	271.36M 55.84%	286.90M 5.72%	209.97M 26.81%	136.91M 34.80%	165.51M 20.89%
research and development expenses	31.00M -	62.57M 101.84%	134.04M 114.21%	204.78M 52.77%	273.04M 33.34%	448.59M 64.29%	582.41M 29.83%	587.96M 0.95%	319.95M 45.58%	240.76M 24.75%	167.65M 30.37%
other expenses		120K -	2.31M 1,828.33%	3.71M 60.37%	-1.27M 134.14%	1.96M 254.78%	-10.09M 614.43%	-6.50M 35.55%	27.65M 525.28%	-102M 468.87%	38.71M 137.95%
cost and expenses	45.13M -	85.80M 90.13%	180.25M 110.08%	269.89M 49.74%	368.12M 36.39%	623.60M 69.40%	856.75M 37.39%	880.25M 2.74%	568.77M 35.39%	285.75M 49.76%	273.76M 4.20%
operating expenses	45.13M -	85.80M 90.13%	180.25M 110.08%	269.89M 49.74%	366.59M 35.83%	622.72M 69.87%	853.77M 37.10%	874.85M 2.47%	529.91M 39.43%	275.67M 47.98%	240.23M 12.86%
interest expense	29K -	152K 424.14%	1.59M 946.71%		-2.00M -	14.62M 830.83%	34.76M 137.70%			-20.63M -	16.35M 179.26%
ebitda	-23.60M -	-60.13M 154.77%	-163.30M 171.56%	-259.65M 59.00%	-333.21M 28.33%	-566.02M 69.87%	-809.33M 42.99%	-635.98M 21.42%	-539.31M 15.20%	-277.21M 48.60%	-167.16M 39.70%
operating income	-24.95M -	-60.63M 143.02%	-169.04M 178.82%	-267.83M 58.44%	-332.17M 24.02%	-572.02M 72.21%	-812.08M 41.97%	-629.51M 22.48%	-590.91M 6.13%	-287.09M 51.42%	-244.26M 14.92%
depreciation and amortization	941K -	4.23M 349.31%	7.42M 75.47%	9.65M 30.04%	13.54M 40.32%	17.16M 26.74%	2.75M 83.99%	-6.47M 335.46%	51.60M 897.80%	9.88M 80.85%	28.52M 188.71%
total other income expenses net	-403K -	-126K 68.73%	-555K 340.48%	-380K 31.53%	-742K 95.26%	-1.04M 39.89%	21.93M 2,212.33%	11.51M 47.53%	28.53M 147.99%	20.63M 27.69%	38.71M 87.62%
income before tax	-25.32M -	-60.51M 138.96%	-166.72M 175.55%	-264.12M 58.42%	-335.43M 27.00%	-555.44M 65.59%	-790.15M 42.26%	-618.01M 21.79%	-562.38M 9.00%	-266.46M 52.62%	-212.04M 20.42%
income tax expense	374K -	-11.80M 3,254.28%	60K 100.51%	-612K 1,120%	210K 134.31%	187K 10.95%	-545K 391.44%	686K 225.87%	258K 62.39%	117K 54.65%	-126K 207.69%
net income	-25.32M -	-48.71M 92.37%	-166.78M 242.41%	-263.51M 57.99%	-335.64M 27.38%	-555.63M 65.54%	-789.61M 42.11%	-618.70M 21.65%	-562.64M 9.06%	-266.58M 52.62%	-211.91M 20.51%
weighted average shs out	12.55M -	26.55M 111.44%	34.67M 30.60%	37.28M 7.54%	43.53M 16.77%	52.03M 19.52%	55.19M 6.07%	62.18M 12.66%	68.91M 10.83%	78.58M 14.04%	109.83M 39.75%
weighted average shs out dil	12.55M -	26.55M 111.44%	34.67M 30.60%	37.28M 7.54%	43.53M 16.77%	52.03M 19.52%	55.19M 6.07%	62.18M 12.66%	68.91M 10.83%	78.58M 14.04%	109.83M 39.75%
eps	-2.02 -	-1.83 9.41%	-4.81 162.84%	-7.07 46.99%	-7.71 9.05%	-10.68 38.52%	-14.31 33.99%	-9.95 30.47%	-8.16 17.99%	-3.39 58.46%	-1.93 43.07%
epsdiluted	-2.02 -	-1.83 9.41%	-4.81 162.84%	-7.07 46.99%	-7.71 9.05%	-10.68 38.52%	-14.31 33.99%	-9.95 30.47%	-8.16 17.99%	-3.39 58.46%	-1.93 43.07%

COM:BLUEBIRDBIO

bluebird bio

Last Close

0.30

22/11 21:00

Market Cap

200.45M

Beta: -

Volume Today

10.33M

Avg: -

Preview